{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-025293","form_type":"8-K","ticker":"CHRS","cik":"0001512762","company_name":"Coherus Oncology, Inc.","filed_at":"2026-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.278272+00:00","generated_at":"2026-05-15T17:38:41.397087+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Coherus Oncology reports FY2025 net loss $183.1M; LOQTORZI revenue doubles to $40.8M","bullets":["LOQTORZI net revenue $40.8M in 2025, more than double $19.1M in 2024; Q4 net revenue $12.4M up 11% QoQ.","Total debt reduced 90% from $480M to $38.8M during 2024-2025; year-end cash $172.1M.","FY2025 GAAP net loss $183.1M ($1.56 diluted) vs $215.4M loss in FY2024; non-GAAP loss $159.2M.","Pipeline: tagmokitug (CCR8) trials in HNSCC, GI, ESCC, CRC; casdozokitug (IL-27) Phase 2 in 1L uHCC; data readouts in mid-2026.","Equity financings: ~$7.9M net from Oct 2025 offering; ~$47.0M net from Feb 2026 public offering."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-025293","json":"https://secwatch.observer/filing/0001104659-26-025293.json","markdown":"https://secwatch.observer/filing/0001104659-26-025293.md","text":"https://secwatch.observer/filing/0001104659-26-025293.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1512762/000110465926025293/0001104659-26-025293-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1512762/000110465926025293/chrs-20260309x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T17:38:41.397087+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4c47a563851bcf8ddb43183dafdeb3bd5ef64c16","claim":"Coherus Oncology, Inc. reported the years ended December 31, 2025 results: revenue $42.2 million.","evidence_excerpt":"Net revenue from continuing operations was $12.7 million and $7.7 million during the three months ended December 31, 2025 and 2024, respectively, and $42.2 million and $26.4 million during the years ended December 31, 2025 and 2024, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1512762/000110465926025293/0001104659-26-025293-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the years ended December 31, 2025"},{"label":"Revenue","value":"$42.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"9511d6856e6acceab0aef6abfc5f7448b59cca80","claim":"Coherus Oncology, Inc. reported the three months ended December 31, 2025 results: revenue $12.7 million.","evidence_excerpt":"Net revenue from continuing operations was $12.7 million and $7.7 million during the three months ended December 31, 2025 and 2024, respectively, and $42.2 million and $26.4 million during the years ended December 31, 2025 and 2024, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1512762/000110465926025293/0001104659-26-025293-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2025"},{"label":"Revenue","value":"$12.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}